Obesity during adulthood tied to increased risk of GI cancer: JAMA

Written By :  Dr. Kamal Kant Kohli
Published On 2023-05-12 05:30 GMT   |   Update On 2023-05-12 07:40 GMT

USA: Overweight and obese body mass index (BMI) in early and middle adulthood may increase the risk of gastrointestinal cancer, a recent study published in JAMA Network Open has suggested. The study also found that frequent aspirin use did not modify this increased risk in overweight and obese individuals.

Doctors have long stressed the importance of maintaining a healthy weight for improving overall health. The study suggests it could reduce future gastrointestinal cancer (GI) risk (colorectal cancer and non-colorectal GI cancers). 

Colorectal cancer is the third most common cancer among men and women in the United States. Although improvements in screening have resulted in many cancers being detected at earlier stages, more than 150,000 new colon and rectal cancer cases are diagnosed annually.

“In a time when obesity rates are rising globally and 70% of the U.S. population alone is considered overweight or obese, understanding the association between obesity and long-term disease risk, such as cancer, is critical for improving public health,” said study lead author Holli Loomans-Kropp, PhD, a cancer control researcher and epidemiologist with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. “Our study suggests that being overweight or obese during several phases of life can increase a person’s risk for gastrointestinal cancers in later adulthood.”

Advertisement

Study design and methods

For this new study, the researchers wanted to understand how body mass index (BMI) changes during several phases of adulthood can influence GI cancer risk.

The team evaluated previously collected data from 131,161 patients enrolled to the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, a multicenter randomized clinical trial that looked at the effectiveness of prostate, lung colorectal and ovarian cancer screening exams for reducing cancer-related deaths. The study was conducted between the years of 1993 and 2001 in participants aged 55 to 74 at the time of enrollment.

Loomans-Kropp notes that obesity results from the buildup and storage of white adipose tissue, or fat. Adipose cells can trigger an inflammatory response and promote immune cell dysfunction that leads to disease development, including cardiovascular diseases like stroke, metabolic conditions like type 2 diabetes, and certain cancers influenced by fat cells.

For this new analysis, age 20 was considered early adulthood, age 50 was considered middle adulthood and age 55 or older was considered later adulthood.

BMI was calculated based on data from self-reported questionnaires completed at the original time of enrollment about weight and height at these age points. Participants were then categorized according to the World Health Organization’s standards of underweight (BMI less than 18.5), normal (18.5-24.9), overweight (25 to 29.9) and obese (BMI over 30). Participants were also asked to report how often they took aspirin or aspirin-containing products in this baseline study. All participants were followed for 13 years or until Dec. 31, 2009, whichever came first.

Study results found an increased GI cancer risk among individuals with overweight and obese BMI at early, middle and later adulthood. It also showed that an increasing BMI over time was associated with an increased risk for colorectal and non-colorectal GI cancers. This association was not modified by regular aspirin use.

“We believe that the results of this study highlight the need to understand better the underlying mechanisms of cancer prevention agents as well as who may or may not benefit from their use. The field of precision prevention is still relatively new but is an exciting avenue for cancer prevention research,” said Loomans-Kropp.

Reference:

Loomans-Kropp HA, Umar A. Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer. JAMA Netw Open. 2023;6(5):e2310002. doi:10.1001/jamanetworkopen.2023.10002


Tags:    
Article Source : JAMA Network Open

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News